Mylan launches generic Aromasin and Pristiq in US

Mylan has announced the launch of new generic versions of the branded therapies Aromasin and Pristiq for the US market.

The company has received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs) for the two therapies, both of which are based on established medicines developed by Pfizer.

Aromasin is indicated for the treatment of certain types of breast cancer in women after menopause, with IMS Health data showing that the original product generated US sales of approximately $100 million (80.13 million pounds) for the 12 months ending January 31st 2017.

The launch of the new generic version will strengthen Mylan's position as the leading supplier of cancer medicines by volume in the US.

Pristiq, meanwhile, is indicated for the treatment of major depressive disorder, and generated $853 million in US product sales during the aforementioned 12-month period.

Currently, Mylan has 241 ANDAs pending FDA approval, which collectively represent approximately $100.8 billion in annual brand sales. Of these, 45 are potential first-to-file opportunities.

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.